Is the efficacy of hormonal therapy affected by lymph node status? Data from the bicalutamide (Casodex) early prostate cancer program

Urology

Volumn 63, Issue 5, 2004, Pages 928-933

  Iversen, Peter ^a   Wirth, Manfred P ^b   See, William A ^b   McLeod, David G ^b   Klimberg, Ira ^b   Gleason, Donald ^b   Chodak, Gerald ^b   Montie, James ^b   Tyrrell, Chris ^b   Wallace, D M A ^b   Delaere, Karl P J ^b   Lundmo, Per ^b   Tammela, Teuvo L J ^b   Johansson, Jan Erik ^b   Morris, Tom ^b   Carroll, Kevin ^b  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

BICALUTAMIDE; PROSTATE SPECIFIC ANTIGEN;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER HORMONE THERAPY; CANCER INHIBITION; CANCER LOCALIZATION; CANCER RADIOTHERAPY; CANCER SURGERY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION ANALYSIS; DOUBLE BLIND PROCEDURE; HUMAN; LYMPH NODE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; ANDROGEN ANTAGONISTS; ANILIDES; ANTINEOPLASTIC AGENTS; DISEASE PROGRESSION; HUMANS; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; NEOPLASM STAGING; PROSTATE-SPECIFIC ANTIGEN; PROSTATECTOMY; PROSTATIC NEOPLASMS; REGRESSION ANALYSIS;

EID: 2342521342     PISSN: 00904295     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.urology.2004.02.011     Document Type: Article

References (9)

1. See W.A., McLeod D., Iversen P., et al. The bicalutamide Early Prostate Cancer Program demography. Urol Oncol. 6:2001;43-47
2. See W.A., Wirth M.P., McLeod D.G., et al. Bicalutamide ('Casodex') 150 mg as immediate therapy either alone or as adjuvant to standard care in patients with localized or locally advanced prostate cancer first analysis of the early prostate cancer program. J Urol. 168:2002;429-435
3. Cheng L., Zincke H., Blute M.L., et al. Risk of prostate carcinoma death in patients with lymph node metastasis. Cancer. 91:2001;66-73
4. Arai Y., Kanamaru H., Yoshimura K., et al. Incidence of lymph node metastasis and its impact on long-term prognosis in clinically localized prostate cancer. Int J Urol. 5:1998;459-465
5. Gervasi L.A., Mata J., Easley J.D., et al. Prognostic significance of lymph nodal metastases in prostate cancer. J Urol. 142:1989;332-336
6. Messing E.M., Manola J., Sarosdy M., et al. Immediate hormonal therapy compared with observation after radical prostatectomy and pelvic lymphadenectomy in men with node-positive prostate cancer. N Engl J Med. 314:1999;1781-1788
7. Granfors T., Modig H., Damber J.-E., et al. Combined orchiectomy and external radiotherapy versus radiotherapy alone for nonmetastatic prostate cancer with or without pelvic lymph node involvement a prospective randomised study. J Urol. 159:1998;2030-2034
8. Schröder FH, Kurth KH, Fossa SD, et al. Early versus delayed endocrine treatment in pN1-3 M0 prostate cancer without local treatment of the primary tumor - results of EORTC 30846 - a phase III study (abstract). J Urol 169(Suppl): 398, 2003
9. van den Ouden D., Tribukait B., Blom J.H.M., et al. Deoxyribonucleic acid ploidy of core biopsies and metastatic lymph nodes of prostate cancer patients impact on time to progression. J Urol. 150:1993;400-406